HC Wainwright Reiterates “$8.00” Price Target for Azurrx Biopharm (AZRX)
Azurrx Biopharm (NASDAQ:AZRX) received a $8.00 price objective from equities research analysts at HC Wainwright in a report released on Monday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 127.92% from the company’s current price.
Azurrx Biopharm (NASDAQ AZRX) traded down 3.42% on Monday, reaching $3.39. 19,447 shares of the company’s stock traded hands. The stock’s market capitalization is $38.08 million. Azurrx Biopharm has a 52-week low of $3.04 and a 52-week high of $5.25. The firm’s 50-day moving average is $3.99 and its 200 day moving average is $3.99.
ILLEGAL ACTIVITY WARNING: “HC Wainwright Reiterates “$8.00” Price Target for Azurrx Biopharm (AZRX)” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/23/azurrx-biopharms-azrx-buy-rating-reiterated-at-hc-wainwright.html.
A hedge fund recently raised its stake in Azurrx Biopharm stock. IHT Wealth Management LLC boosted its position in shares of Azurrx Biopharm (NASDAQ:AZRX) by 15.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,498 shares of the company’s stock after purchasing an additional 464 shares during the quarter. IHT Wealth Management LLC’s holdings in Azurrx Biopharm were worth $486,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 5.86% of the company’s stock.
About Azurrx Biopharm
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
Receive News & Ratings for Azurrx Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azurrx Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.